A previous Canadian study, which focused on the molecular profiling of mutations in NSCLC, found a lower prevalence of EGFR mutations (6.9%) in their cohort, but the cohort was primarily composed of early stage cases [16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.